Have you read these stories?

Why robots pose a threat to Wall Street's highest-paying jobs

The use of algorithms in electronic markets also poses a challenge for regulators.

diabetes mellitus

Dec 08, 2019, 01.51 AM IST



Biocon sees a sweet spot with its affordable insulin in US

The biotech firm is also planning to provide its rh-insulin to middle- and low-income countries at less than 10 cents a day. Biocon Biologics is chasing a revenue target of $1 billion in financial year 2021-22. In the previous fiscal year, its revenue had topped $200 million.

Volume with low cost is Biocon Biologics’ big plan

The Biocon subsidiary will chart a path that ensures high volumes and low costs, unlike co...

Parliamentary panel recommends integration of Indian Systems of Medicine with modern treatment

The Department-related Parliamentary Standing ...

ET Prime Distribution
Load More...

Other useful Links

Copyright © 2019 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service